Century Capital Management LLC bought a new stake in shares of Nektar Therapeutics (NASDAQ:NKTR) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 20,691 shares of the biopharmaceutical company’s stock, valued at approximately $405,000.

Other institutional investors also recently bought and sold shares of the company. Flinton Capital Management LLC raised its stake in shares of Nektar Therapeutics by 11.1% during the first quarter. Flinton Capital Management LLC now owns 4,480 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 448 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Nektar Therapeutics by 14.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 692 shares in the last quarter. Meadow Creek Investment Management LLC raised its stake in shares of Nektar Therapeutics by 11.1% during the first quarter. Meadow Creek Investment Management LLC now owns 6,160 shares of the biopharmaceutical company’s stock valued at $145,000 after acquiring an additional 616 shares in the last quarter. LS Investment Advisors LLC raised its stake in shares of Nektar Therapeutics by 8.8% during the second quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock valued at $129,000 after acquiring an additional 535 shares in the last quarter. Finally, Glen Harbor Capital Management LLC raised its stake in shares of Nektar Therapeutics by 11.1% during the first quarter. Glen Harbor Capital Management LLC now owns 7,840 shares of the biopharmaceutical company’s stock valued at $184,000 after acquiring an additional 784 shares in the last quarter. 95.15% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts recently commented on the stock. BidaskClub raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. Jefferies Group LLC reaffirmed a “buy” rating and set a $23.00 price target on shares of Nektar Therapeutics in a research report on Friday, August 18th. HC Wainwright assumed coverage on Nektar Therapeutics in a research report on Monday, August 7th. They set a “buy” rating and a $31.00 price target on the stock. Zacks Investment Research downgraded Nektar Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Finally, William Blair reaffirmed an “outperform” rating on shares of Nektar Therapeutics in a research report on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the company. Nektar Therapeutics presently has a consensus rating of “Buy” and an average target price of $26.10.

In related news, CAO Jillian B. Thomsen sold 2,648 shares of the firm’s stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $19.32, for a total transaction of $51,159.36. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Howard W. Robin sold 91,714 shares of the firm’s stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $19.26, for a total transaction of $1,766,411.64. Following the transaction, the chief executive officer now directly owns 152,504 shares in the company, valued at approximately $2,937,227.04. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 320,962 shares of company stock worth $6,615,210. Insiders own 5.44% of the company’s stock.

Nektar Therapeutics (NASDAQ:NKTR) opened at 21.89 on Wednesday. The firm’s market cap is $3.42 billion. The firm has a 50 day moving average of $20.28 and a 200-day moving average of $19.41. Nektar Therapeutics has a 12 month low of $11.41 and a 12 month high of $24.88.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.04). The company had revenue of $34.60 million during the quarter, compared to analysts’ expectations of $33.64 million. Nektar Therapeutics had a negative return on equity of 1,223.34% and a negative net margin of 157.14%. Nektar Therapeutics’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same period last year, the company earned ($0.36) earnings per share. On average, equities research analysts forecast that Nektar Therapeutics will post ($0.94) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Century Capital Management LLC Invests $405,000 in Nektar Therapeutics (NKTR) Stock” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/century-capital-management-llc-invests-405000-in-nektar-therapeutics-nktr-stock/1558793.html.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.